논문번호 | 294 | ||
논문제목(영문) | Drug-coated Balloon Angioplasty Versus Drug-eluting Stenting for Femoropopliteal Arterial Disease: A Review of the Current Status. | ||
국내외구분 | 국외 | SCI여부 | SCI(E) |
연구책임자역할 | 공저자 | ||
주저자명 | Sim DS | ||
교신저자명 | Mathur A | ||
공동저자명 | Jeong MH, Ahn Y, Mena-Hurtado C, Martin J | ||
게제년월일 | 2022-01-31 | ||
ISSN | 2639-8486 | ||
Impact Factor | 0 | ||
학술지명 | Cardiol Vasc Res (Wilmington) | ||
서지사항 | 0집 / 6권 / 1호, 페이지(1 - 9) | ||
요약초록문 (Abstract) 입력 |
Endovascular procedures are frequently performed for symptomatic femoropopliteal disease. Drug-eluting stents (DES) and drug-coated balloons (DCB) were introduced to improve long-term outcomes and demonstrated superior outcomes to percutaneous transluminal angioplasty in randomised clinical trials. Femoropopliteal disease, however, can be challenging to treat using an endovascular approach as this segment suffers increased biomechanical stress during extremity movements, which may lead to chronic vascular injury or even stent fracture. The advantages of DCB include the direct and homogeneous delivery of an antiproliferative agent to the arterial wall, and the ability to reach tortuous and longer lesions without a vascular implant; however, the lack of scaffold makes the intervention prone to significant recoil. Even though the use of DCB, a leave-nothing-behind strategy, may appear desirable, the need for bailout stenting will increase as lesions become more complex. This review summarises and compares the currently available evidence regarding the use of DCB and DES in the treatment of femoropopliteal disease. |
||
파일 |
C 294.pdf (400.5K) DATE : 2024-06-18 08:56:42 |
전라남도 장성군 남면 삼태리 산 109 나노바이오연구원 3층 306호 TEL : 061-392-6243 Fax: 061-392-6243
Copyright ⓒ 2014 Korea Cardiovascular Stent Research Institute. All right Reserved